INTRODUCTION

Thallium is one of the most toxic heavy metals and is widely used in the manufacturing of highly regulated products (Baldwin, 1999). The hallmark symptoms of thallium poisoning are digestive issues, alopecia, and polyneuropathy, each of which present at different stages following poisoning (Galván-Arzate, 1998). Here, we present findings from a patient who was poisoned with thallium on two separate occasions. We followed up the patient for 6 years to determine the long-term outcomes of his thallium poisoning.

METHODS

This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The Institutional
ethics committee of Maoming people’s Hospital had granted approval for our work.

We determined the detailed long-term outcomes of a patient with two separate occasions of thallium poisoning. A PubMed literature review was performed using the terms “thallium poisoning” or “thallium intoxication.” Publications from January 1990 to September 2020 reporting more than two cases of thallium poisoning with detailed manifestations, treatments, and outcomes were selected. Demographics, intervals from thallium exposure to onset, clinical symptoms, determinations of thallium levels in urine, treatments, and outcome data were extracted from these selected studies.

3 | RESULTS

3.1 | Case details

A 43-year-old man developed acute abdominal colic and diarrhea a few hours after a barbecue dinner. Gastroenteritis was diagnosed. Then, the patient continued to complain about the numbness of his limbs. His individual and family histories were unremarkable. Neurologic examination suggested hypoesthesia of the lower extremities. Blood glucose, urine glucose, and urine ketones were all positive. Nerve conduction studies demonstrated features of peripheral sensorimotor neuropathy (Figure 1a). Hence, a diagnosis of diabetic peripheral neuropathy was considered at this time. Following a combined treatment, the patient’s symptoms gradually improved and he was subsequently discharged.

Twenty-one months later, an aching pain in both distal lower limbs was experienced by the patient on one afternoon, which then progressed to extremely painful paresthesia, myalgia, and weakness in both of his legs. Alopecia started in the third week. Neurologic symptoms deteriorated continually in the fourth week. Thereafter, he was then transferred to another hospital. Guillain–Barré Syndrome (GBS) was diagnosed and treated. Unfortunately, the patient’s specific symptoms were not improved at this time. Finally, the patient was transferred to the Department of Neurology at our hospital-Maoming people’s hospital.

Neurologic examination revealed that the patient was confused and exhibited incoherent speech, dysesthesia, and a symmetrical decrease in muscle strength of the lower extremities (4/5 in proximal muscles and 0/5 in distal muscles), along with an absence of tendon reflexes. The patient’s score on the Mini-Mental State Examination (MMSE) was 13, and his Barthel index (BI) was 20. Results of routine laboratory tests were all normal. Electrocardiographic data indicated tachycardia. Nerve conduction studies demonstrated features of peripheral sensorimotor neuropathy, similar to the findings during the aforementioned first onset of symptoms (Figure 1b). Results of brain magnetic resonance imaging were normal.

Considering the presence of both severe peripheral neuropathies and alopecia, heavy metal intoxication was suspected. Testing for arsenic, mercury, and lead were all negative. Blood and urinary thallium concentrations of the patient were determined by atomic absorption spectrophotometry, and they were all significantly elevated compared with those of normal levels. Thallium levels were 336.5 μg/L in the patient’s blood (normal < 10 μg/L) and 252.3 μg/L in the patient’s urine (normal < 20 μg/L). Hence, the diagnosis of thallium poisoning was confirmed. Prussian blue (250 mg/kg/d in 4 divided doses) was administered for 2 months until blood thallium concentrations returned to normal levels. Following treatment, the patient’s symptoms were alleviated significantly, although lower extremity paralysis, numbness, and mild cognitive impairment were still present (MMSE 19, BI 20). The patient was then transferred to our rehabilitation department for long-term rehabilitation treatment.

![Figure 1](image-url) Neurophysiological evaluation of thallium poisoning at the onset of symptoms and at different follow-up periods. Peripheral nerve conduction data showing reduced conduction velocity with mildly reduced compound muscle action potentials at the first onset of symptoms (a), which remained unchanged at the second onset of symptoms (b), but the evoked potential amplitude was absence, and the conduction velocity was nondetectable at a 2-year follow-up (c).
At a 6-month follow-up after treatment, the clinical cutaneous features had subsided completely. Considering that the patient had diabetes mellitus, blood sugar levels remained normal upon treatment with insulin. Muscle strengths of the patient’s legs were graded 4/5 in proximal muscles and 1/5 in distal muscles, and the MMSE and BI scores improved to 23 and 20, respectively.

At a 2-year follow-up, there was residual mild weakness and numbness of the distal lower extremities. Muscle strength was graded 3/5 in distal muscles. The MMSE and BI scores were 29 and 75, respectively. The signs of electrophysiology aggravated comparing to previous investigations. Main findings of nerve conduction showed the evoked potential amplitude was absence, and the conduction velocity was nondetectable at a 2-year follow-up (Figure 1c). At a 6-year follow-up, the record muscle strengths and MMSE and BI scores did not exhibit any improvements compared with those at the previous follow-up. The detailed scores at different time points are listed in Table 1.

Since the patient was suspected of being poisoned, an epidemiological study was conducted to investigate his work and home environments. Following this investigation, a criminal suspect confessed to two instances of adulterating thallium sulfate in the patient’s beverage, although the dosages of thallium sulfate were unable to be determined. The relationship between the two incidents of thallium poisoning and variation in the main clinical manifestations from the first onset to 6 years into follow-ups is shown in Figure 2.

3.2 | Literature review

Nine articles including 98 cases with thallium poisoning were retrieved in our literature review (Table 2) (Afshari et al., 2012; Al Hammouri et al., 2011; Desenclos et al., 1992; Di Candia et al., 2020; Li et al., 2014; Lin et al., 2019; Meggs et al., 1994; Sun et al., 2012; Zhang et al., 2014). The median age of the patients was 30 years (range 2–73 years). The number of intervening days from exposure to onset was 1–6 days. The clinical characteristics of these patients were systematically analyzed and are presented in Table 2. We found that polyneuropathy (82%), alopecia (68%), and abdominal pain (51%) were the most frequent clinical manifestations, which is consistent with a previous study (Baldwin & Marshall, 1999). Determination of thallium in urine ranged from 68 to 42,000 μg/L. The treatments included symptomatic treatment, prussian blue alone, or combined with hemoperfusion, hemodialysis, plasma exchange, or continuous renal replacement therapy (CRRT). In terms of outcomes, we determined that 55% of patients had subsided symptoms, 12% died, and 20% of patients remained with neurologic sequelae. However, statistical bias may have existed due to missing data.

4 | DISCUSSION

Thallium poisoning most often occurs after accidental poisoning or an attempted homicide (Rodríguez-Mercado and Altamirano-Lozano, 2013). The primary route of poisoning is via ingestion, although rare cases of skin and respiratory absorption have also been reported. The mechanisms of thallium toxicity involve the substitution of potassium in Na-K ATPases, because thallium closely resembles potassium in terms of its ionic size and charge, and thallium also interacts with sulphhydryl groups of molecules in mitochondrial membranes and neuronal axons (Baldwin, 1999).

A comprehensive literature search from PubMed identified nine studies of three or more cases of thallium poisoning each. In these cases, the durations from symptom onset to diagnosis ranged from several hours to four years, even after autopsy (Hirata et al., 1998; Li et al., 2014), and this wide range may be due to the following factors. Characteristics of thallium poisoning are attributed to the corresponding dose, as well as individual susceptibility and metabolism. In previous studies (Herrero et al., 1995), thallium has been shown to affect multiple organs and to induce several clinical symptoms, including gastrointestinal, neurologic, dermatological, circulatory, and respiratory symptoms. Gastrointestinal symptoms presenting with nausea, vomiting, abdominal pain, and distension are usually the first characteristics of thallium poisoning and can be easily ignored. Neurologic damage following thallium poisoning can include polyneuropathy (presenting with pinprick pain), paresthesia, dysesthesia, and/or hypealgesia in the distal lower limbs. About 2–3 weeks later, characteristics of dermatological changes can include alopecia, Mees’ lines, and/or erythematous skin rashes. In addition, thallium poisoning is often accompanied by nonspecific symptoms, such as headaches, myalgia, depression, and sleeping disturbances. Results of routine laboratory tests are usually unremarkable, although hepatic/renal damage, abnormal full blood counts, hyponatremia, hypokalemia, and/or high blood glucose may be detected during the initial stage of severe cases (Zhu et al., 2019). In our present case, the evidence that the patient presented high blood glucose may have been a coincidence due to him being diabetic and without recent exogenous insulin at the time of the follow-up.

Although the distinctive clinical features of thallium poisoning comprise gastrointestinal presentation, alopecia, and

| Time       | First onset | Second onset | After treatment | 6-month follow-up | 1-year follow-up | 2-year follow-up | 6-year follow-up |
|------------|-------------|--------------|----------------|-------------------|------------------|------------------|------------------|
| MS         | 5           | 0            | 1              | 1                 | 2                | 3                | 3                |
| MMSE       | 30          | 13           | 19             | 23                | 24               | 29               | 29               |
| BI         | 100         | 15           | 20             | 20                | 35               | 75               | 75               |
polyneuropathy (Galván-Arzate, 1998), these features are not always present initially during clinical examinations, which can lead to misdiagnoses. In previous cases (Baldwin & Marshall, 1999), thallium poisoning has often been misdiagnosed as gastroenteritis, peripheral neuropathy, and GBS at the early stages of symptoms.

In our present case report, retrospective analysis showed that the patient's symptoms were typical of thallium poisoning. Therefore, a lack of experience of the attending physician who initially assessed this patient may have played an important role in the initial misdiagnosis.

Thallium intoxication can severely affect the nervous system, including peripheral (sensorimotor neuropathy), central (altered mental status, convulsions, and extrapyramidal and cerebellar dysfunctions), and autonomic (tachycardia, hypertension, and urinary retention) neural systems. At considerably high thallium doses, coma and death may occur (Tsai et al., 2006). A previous study reported a case of neurologic symptoms that rapidly and severely deteriorated after the second thallium ingestion, but that did not exhibit any other symptoms (Kuroda et al., 2016). The long-term prognosis of thallium poisoning depends on the total dose ingested, the timing of treatment, and the individual susceptibility of each patient (Huang et al., 2014). Most of the symptoms of thallium poisoning can be completely reversed, but mild or moderate neurologic sequelae may last for a long time. In the outcome of review studies, we found that 55% patients recovered, 12% died, and 20% patients remained with neurologic sequelae presenting with paresthesia, weakness in the extremities, and/or cognitive dysfunction. In the present case report, after treatment with Prussian blue and long-term rehabilitation, at a 6-year follow-up, the patient's muscle strength in the distal muscles of his legs improved (from 0 to 3), as did his BI (from 15 to 75). Nonetheless, neuroelectrophysiological signatures were not improved at this follow-up. Nerve conduction was undetected 2 years later, and electromyographic data were suggestive of axonal degeneration. In a previous study of a patient with thallium poisoning, sequential nerve conductions revealed that nerve conduction was undetected 2 years after initial symptoms, despite the patient otherwise improving clinically (Dumitru & Kalantri, 1990). This finding suggests the possibility of clinical improvements following thallium poisoning, despite continued deterioration of electromyographic signatures. The prominent central neurologic symptoms of our present case report—which included confusion, psychosis, and cognitive deficits—improved significantly at follow-ups. MMSE scores gradually increased from 13 to 29, but subtle cognitive deficits persisted even at a 6-year follow-up.

FIGURE 2. The relationship between two incidents of thallium poisoning and variation in the main clinical manifestations from the first onset to a 6-year follow-up.

5 | CONCLUSIONS

In our present case report, thallium intoxication may have been initially identified if neurologic symptoms had occurred concurrently with gastrointestinal and cutaneous symptoms. Neurologic damage represented the main sequelae of thallium poisoning in our present case report.
TABLE 2  Systematic review of cases of thallium poisoning

| References                      | Afshari et al., 2012 | Desenclos et al., 1992 | Di Candia et al., 2020 | Li, et al., 2014 | Lin et al., 2019 | Meggs et al., 1994 | Sun et al., 2012 | Zhang et al., 2014 | Al Hammouri et al., 2011 | Total |
|--------------------------------|----------------------|------------------------|------------------------|------------------|------------------|-------------------|------------------|-------------------|------------------------|-------|
| Numbers                        | 3                    | 3                      | 8                      | 13               | 34               | 4                 | 14               | 9                 | 10                     | 98    |
| Age (year)                     | 26 (22–32)           | 24 (16–41)             | –                      | 37 (15–53)       | 39 (26–53)       | –                 | 36 (2–73)        | –                 | 18 (2–42)              | 30 (2–73) |
| Interval from exposure to onset (d)| –                    | 2 (1–3)                | –                      | 2.3 (1–6)        | –                | 2.5 (1–3)         | –                | 2 (1–3)           | 2 (1–3)                | 2 (1–6) |
| Symptoms                       |                      |                        |                        |                  |                  |                   |                  |                   |                        |       |
| Gastrointestinal               |                      |                        |                        |                  |                  |                   |                  |                   |                        |       |
| Nausea and vomiting            | 0                    | 1                      | 8                      | –                | 1                | 3                 | 7                | 6                 | 8                      | 34 (34%) |
| Abdominal pain                 | 0                    | 3                      | 8                      | –                | 12               | 3                 | 11               | 6                 | 8                      | 51 (52%) |
| Abdominal distension           | 0                    | 1                      | 8                      | –                | 9                | –                 | 6                | 4                 | 8                      | 36 (36%) |
| Neurologic                     |                      |                        |                        |                  |                  |                   |                  |                   |                        |       |
| Polynuropathy                  | 1                    | 3                      | 8                      | 12               | 31               | 4                 | 14               | 2                 | 7                      | 82 (83%) |
| Tremor or weakness in extremities| 3                    | 3                      | 8                      | 8                | 1                | –                 | 7                | 2                 | 8                      | 40 (40%) |
| Dizziness and headaches        | 0                    | 0                      | –                      | 3                | –                | –                 | –                | –                 | –                      | 19 (19%) |
| Vision loss                    | 3                    | 0                      | –                      | –                | –                | –                 | –                | –                 | 3                      | 6 (6%) |
| Delirium                       | 0                    | 2                      | –                      | 5                | –                | –                 | –                | –                 | 1                      | 16 (16%) |
| Coma                           | 0                    | 2                      | –                      | 1                | 1                | –                 | 1                | –                 | 6                      | 11 (11%) |
| Cardiac arrhythmias            | 0                    | 2                      | –                      | 3                | –                | 2                 | –                | 1                 | –                      | 8 (8%) |
| Dyspnea                        | –                    | 3                      | 3                      | –                | –                | –                 | –                | 1                 | –                      | 7 (7%) |
| Dermatological                 |                      |                        |                        |                  |                  |                   |                  |                   |                        |       |
| Alopecia                       | 3                    | 3                      | –                      | 10               | 19               | 3                 | 14               | 9                 | 7                      | 68 (69%) |
| Mees' lines                    | 0                    | –                      | –                      | 3                | –                | –                 | –                | –                 | 2                      | 1 (6%) |
| Erythematous skin rashes       | 0                    | –                      | –                      | 2                | –                | –                 | –                | 2                 | 4                      | 9 (9%) |
| Fatigue                        | 3                    | –                      | 8                      | –                | –                | –                 | 14               | 9                 | –                      | 34 (34%) |
| Insomnia                       | 1                    | –                      | 3                      | –                | –                | 1                 | –                | –                 | 9                      | 14 (14%) |
| Thallium in Urine (μg/L)       | 2,000–3,000          | 68–26,000              | 16,300–42,000         | 231–12,840       | –                | 1,083.7–9,569     | 956.5–11,285      | 4,343.5–9,998       | 452–2,909              | 68–42,000 |
| Treatments                     | Not PB nor PF        | –                      | PB (8)                 | PB (8); PB + HP (5) | PB (16); PB + HP (12)/PE (1)/CRRT (1) | PB + HD (4) | PB (2) PB + HD (12) | PB + HP/HD/CRRT (9) | PB (1); PB + HD (9) | – |
| Outcome                        |                      |                        |                        |                  |                  |                   |                  |                   |                        |       |
| Neurologic sequelae            | 1                    | 2                      | –                      | 11               | 5                | 0                 | 1                | 0                 | –                      | 20 (20%) |
| Dead                           | 0                    | 1                      | 3                      | 2                | 0                | 0                 | 0                | 0                 | 3                      | 9 (12%) |
| Complete reversal              | 2                    | 0                      | –                      | 26               | 4                | 13               | 9                | –                 | 54 (55%)              |       |

Abbreviations: –, means not available; CRRT, continuous renal replacement therapy; HD, hemodialysis; HP, hemoperfusion; PB, Prussian blue; PE, plasma exchange.
ACKNOWLEDGMENTS
Funding was received from the High-level Hospital Construction Research Project of Maoming People's Hospital, Reference NO. Yueweihan (2018)413.

CONFLICT OF INTEREST
None of the authors has any conflict of interest to disclose.

AUTHOR CONTRIBUTIONS
We declare that all the listed authors have participated actively in the report. GL designed the report and wrote the protocol. HL wrote the first draft of the manuscript. GL and HL managed the literature searches and analyses. GL and HL took overall responsibility.

ETHICAL APPROVAL
We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

PEER REVIEW
The peer review history for this article is available at https://publo ns.com/publon/10.1002/brb3.2032.

DATA AVAILABILITY STATEMENT
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Hailing Liu https://orcid.org/0000-0001-7247-4633
Geng Liao https://orcid.org/0000-0003-0690-4871

REFERENCES
Afshari, R., Mégarbane, B., & Zavar, A. (2012). Thallium poisoning: One additional and unexpected risk of heroin abuse. Clinical Toxicology (Philadelphia, Pa), 50, 791-792. https://doi.org/10.3109/15563650.2012.713110

Al Hammouri, F., Darwazeh, G., Said, A., & Ghosh, R. A. (2011). Acute thallium poisoning: Series of ten cases. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, 7, 306–311. https://doi.org/10.1007/s13181-011-0165-3

Baldwin, D. R. M. W. (1999). Heavy metal poisoning and its laboratory investigation. Annals of Clinical Biochemistry, 36, 267–300. https://doi.org/10.1177/000456329903600301

Baldwin, D. R., & Marshall, W. J. (1999). Heavy metal poisoning and its laboratory investigation. Annals of Clinical Biochemistry, 36(Pt 3), 267–300. https://doi.org/10.1177/000456329903600301

Desenclos, J. C., Wilder, M. H., Coppenger, G. W., Sherin, K., Tiller, R., & VanHook, R. M. (1992). Thallium poisoning: An outbreak in Florida. 1988. Southern Medical Journal, 85, 1203–1206. https://doi.org/10.1097/00007611-199212000-00012

Di Candia, D., Muccino, E., Battistini, A., Boracchi, M., Gentile, G., & Zoja, R. (2020). Thallium toxicity due to adulterated infusion with thallium sulfate in eight members belonging to the same family nucleus: Autopsy findings and ICP-MS analysis (inductively coupled plasma mass spectrometry) in a triple homicide. Legal Medicine (Tokyo, Japan), 42, 101661. https://doi.org/10.1016/j.legalmed.2019.101661

Dumitru, D., & Kalantri, A. (1990). Electrophysiologic investigation of thallium poisoning. Muscle and Nerve, 13, 433–437. https://doi.org/10.1002/mus.880130510

Galván-Arzate, S. S. A. (1998). Thallium toxicity. Toxicology Letters, 99, 1–13. https://doi.org/10.1016/S0378-4274(98)00126-X

Herrero, F., Fernandez, E., Gomez, J., Pretel, L., Canizares, F., Frias, J., & Escribano, J. B. (1995). Thallium poisoning presenting with abdominal colic, paresthesia, and irritability. Journal of Toxicology - Clinical Toxicology, 33, 261–264. https://doi.org/10.3109/1556365950 917995

Hirata, M., Taoda, K., Ono-Ogasawara, M., Takaya, M., & Hisanaga, N. (1998). A probable case of chronic occupational thallium poisoning in a glass factory. Industrial Health, 36, 300–303. https://doi. org/10.2486/indhealth.36.300

Huang, C., Zhang, X., Li, G., Jiang, Y., Wang, Q., & Tian, R. (2014). A case of severe thallium poisoning successfully treated with hemoperfusion and continuous veno-venous hemofiltration. Human and Experimental Toxicology, 33, 554–558. https://doi.org/10.1177/09603 27113499039

Li, J. M., Wang, W., Lei, S., Zhao, L. L., Zhou, D., & Xiong, H. (2014). Misdagnosis and long-term outcome of 13 patients with acute thallium poisoning in China. Clinical Toxicology, 52, 181–186. https://doi.org/10.3109/15563650.2014.892123

Kuroda, H., Mukai, Y., Nishiyama, S., Takeshita, T., Tateyama, M., Takeda, A., & Aoki, M. (2016). Tardily accelerated neurologic deterioration in two-step thallium intoxication. Journal of Clinical Neuroscience, 34, 234–236. https://doi.org/10.1016/j.jocn.2016.09.003

Lin, G., Yuan, L., Peng, X., Long, J., Wang, C., Bai, L., Lu, X., Dong, J., Liu, Y., Wang, Y., & Qiu, Z. (2019). Clinical characteristics and treatment of thallium poisoning in patients with delayed admission in China. Medicine, 98, e16471. https://doi.org/10.1097/MD.0000000000 016471

Meggs, W. J., Hoffman, R. S., Shih, R. D., Weisman, R. S., & Goldfrank, L. R. (1994). Thallium poisoning from maliciously contaminated food. Journal of Toxicology - Clinical Toxicology, 32, 723–730. https://doi.org/10.3109/1556365940917797

Rodríguez-Mercado, J. J., & Altamirano-Lozano, M. A. (2013). Genetic toxicity of thallium: A review. Drug and Chemical Toxicology, 36, 369–383. https://doi.org/10.3109/01480545.2012.710633

Sun, T. W., Xu, Q. Y., Zhang, X. J., Wu, Q., Liu, Z. S., Kan, Q. C., Sun, C. Y., & Wang, L. (2012). Management of thallium poisoning in patients with delayed hospital admission. Clinical Toxicology (Philadelphia, Pa), 50, 65–69. https://doi.org/10.3109/15563650.2011.638926

Tsai, Y. T., Huang, C. C., Kuo, H. C., Wang, H. M., Shen, W. S., Shih, T. S., & Chu, N. S. (2006). Central nervous system effects in acute thallium poisoning. Neurotoxicology, 27, 291–295. https://doi.org/10.1016/j. neuro.2005.10.009

Zhang, H. T., Qiao, B. P., Liu, B. P., & Zhao, X. G. (2014). Study on the treatment of acute thallium poisoning. The American Journal of the Medical Sciences, 347, 377–381. https://doi.org/10.1097/MAJ.0b013 e318298de9c

Zhu, B., Liang, C., Yan, S., Huang, K., Xia, X., Hao, J., Zhu, P., & Tao, F. (2019). Association between serum thallium in early pregnancy and risk of gestational diabetes mellitus: The Ma'anshan birth cohort study. Journal of Trace Elements in Medicine and Biology: Organ of the Society for Minerals and Trace Elements (GMS), 52, 151–156. https://doi.org/10.1016/j.jtemb.2018.12.011

How to cite this article: Liu H, Liao G. Long-term misdiagnosis and neurologic outcomes of thallium poisoning: A case report and literature review. Brain Behav. 2021;11:e02032. https://doi.org/10.1002/brb3.2032